Evidence map›Paper›PMID 38114276›Full record

ArticleBMJ open2023

Developing a model for decision-making around antibiotic prescribing for patients with COVID-19 pneumonia in acute NHS hospitals during the first wave of the COVID-19 pandemic: qualitative results from the Procalcitonin Evaluation of Antibiotic use in COVID-19 Hospitalised patients (PEACH Study).

Josie Henley, Lucy Brookes-Howell, Joanne Euden, Philip Pallmann, Martin Llewelyn, Philip Howard, Neil Powell, Paul Dark, Tamas Szakmany, Thomas P Hellyer and 10 more

Open access · goldAbstract read
PubMed Publisher
In one paragraph

Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 12 institutions in 1 country.

Josie HenleySchool of Social Sciences, Cardiff University, Cardiff, UK HenleyJ@cardiff.ac.uk.ORCID 0000-0002-2709-900X
Lucy Brookes-HowellCardiff University Centre for Trials Research, Cardiff, UK.ORCID 0000-0002-8263-7130
Joanne EudenCollege of Biomedical and Life Sciences, Cardiff University Centre for Trials Research, Cardiff, UK.ORCID 0000-0002-2844-6878
Philip PallmannCollege of Biomedical and Life Sciences, Cardiff University Centre for Trials Research, Cardiff, UK.ORCID 0000-0001-8274-9696
Martin LlewelynBrighton and Sussex Medical School, University of Sussex and University Hospitals Sussex NHS Foundation Trust, Brighton, UK.ORCID 0000-0002-6811-1124
Philip HowardSchool of Healthcare, University of Leeds, Leeds, UK.ORCID 0000-0002-5096-0240
Neil PowellRoyal Cornwall Hospitals NHS Trust, Truro, UK.ORCID 0000-0002-6113-9810
Paul DarkIntensive Care Unit, University of Manchester, Salford, UK.ORCID 0000-0003-3309-0164
Tamas SzakmanyCritical Care Directorate, Aneurin Bevan University Health Board, Newport, UK.ORCID 0000-0003-3632-8844
Thomas P HellyerTranslational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.ORCID 0000-0001-5346-7411
Mahableshwar AlburMicrobiology, North Bristol NHS Trust, Bristol, UK.ORCID 0000-0001-9792-7280
Ryan HamiltonSchool of Pharmacy, De Montfort University, Leicester, UK.
Graham PrestwichPublic Patient Representative, Leeds, UK.
Margaret OgdenFaculty of Social Sciences, University of Stirling, Stirling, UK.
Wakunyambo MabosheCardiff University Centre for Trials Research, Cardiff, UK.ORCID 0000-0002-9195-0030
Jonathan SandoeDepartment of Microbiology, The General Infirmary at Leeds, Leeds, UK.ORCID 0000-0003-0193-8677
Emma Thomas-JonesCardiff University Centre for Trials Research, Cardiff, UK.ORCID 0000-0001-7716-2786
Enitan CarrolInstitute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK.ORCID 0000-0001-8357-7726
PEACH study group (Procalcitonin Evaluation of Antibiotic use in COVID-19 Hospitalised patients)
PEACH consortium (Procalcitonin Evaluation of Antibiotic use in COVID-19 Hospitalised patients)
Cardiff University · GBAneurin Bevan University Health Board · GBBrighton and Sussex Medical School · GBDe Montfort University · GBLeeds General Infirmary · GBNewcastle University · GBNorth Bristol NHS Trust · GBRoyal Cornwall Hospital Trust · GBUniversity of Leeds · GBUniversity of Liverpool · GBUniversity of Manchester · GBUniversity of Stirling · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo explore and model factors affecting antibiotic prescribing decision-making early in the pandemic.

designSemistructured qualitative interview study.

settingNational Health Service (NHS) trusts/health boards in England and Wales.

participantsClinicians from NHS trusts/health boards in England and Wales.

methodIndividual semistructured interviews were conducted with clinicians in six NHS trusts/health boards in England and Wales as part of the Procalcitonin Evaluation of Antibiotic use in COVID-19 Hospitalised patients study, a wider study that included statistical analysis of procalcitonin (PCT) use in hospitals during the first wave of the pandemic. Thematic analysis was used to identify key factors influencing antibiotic prescribing decisions for patients with COVID-19 pneumonia during the first wave of the pandemic (March to May 2020), including how much influence PCT test results had on these decisions.

resultsDuring the first wave of the pandemic, recommendations to prescribe antibiotics for patients with COVID-19 pneumonia were based on concerns about secondary bacterial infections. However, as clinicians gained more experience with COVID-19, they reported increasing confidence in their ability to distinguish between symptoms and signs caused by SARS-CoV-2 viral infection alone, and secondary bacterial infections. Antibiotic prescribing decisions were influenced by factors such as clinician experience, confidence, senior support, situational factors and organisational influences. A decision-making model was developed.

conclusionThis study provides insight into the decision-making process around antibiotic prescribing for patients with COVID-19 pneumonia during the first wave of the pandemic. The importance of clinician experience and of senior review of decisions as factors in optimising antibiotic stewardship is highlighted. In addition, situational and organisational factors were identified that could be optimised. The model presented in the study can be used as a tool to aid understanding of the complexity of the decision-making process around antibiotic prescribing and planning antimicrobial stewardship support in the context of a pandemic. TRIAL REGISTRATION NUMBER: ISRCTN66682918.

Indexed as

Bacterial InfectionsCOVID-19Anti-Bacterial AgentsHospitalsHumansPandemicsProcalcitoninSARS-CoV-2State MedicineAnti-Bacterial AgentsProcalcitoninCOVID-19infection controlinfectious diseases

Identifiers

PMID38114276
OpenAlexW4389980498

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.